MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ymgme.2022.106981

Медицинская библиотека · Molecular genetics and metabolism · 2022

Patient reported quality of life and medication adherence in Fabry disease patients treated with migalastat: A prospective, multicenter study.

Müntze Jonas, Lau Kolja, Cybulla Markus, Brand Eva, Cairns Tereza, Lorenz Lora, Üçeyler Nurcan, Sommer Claudia, Wanner Christoph, Nordbeck Peter

Многоцентровое исследованиеСтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

AIMS: Chaperone therapy with migalastat is a novel therapy option in Fabry disease (FD). In contrast to biweekly intravenous enzyme-replacement-therapy in a healthcare setting, oral delivery of migalastat every other day relies on the patient self-administration. Therapy adherence to migalastat and patient reported outcomes have not yet been studied in a real-world scenario.

METHODS AND

RESULTS

Prospective multicenter 'MigALastat Therapy Adherence among FABRY patients' (MALTA-FABRY) study examined therapy adherence and patient-reported outcomes including quality of life in FD-patients receiving migalastat. Outcome measurements were elicited by the 'Medication Adherence Questionnaire (MAQ)', 'SF-36' and 'Fabry Pain Questionnaire' over a follow-up period of 24 months. Therapy adherence was graded as high (MAQ score of 4), medium (score of 2-3) or low (score 0-1). Within the recruitment period between 2017 and 2021, 40 patients (19 females) from 3 German FD-centers were included in the study. Nearly all patients (n = 37, 92.5%) showed good therapy adherence (MAQ6Mmean:3.93, MAQ12Mmean:3.71 and MAQ24Mmean:3.7). Only one patient fulfilled criteria for low adherence. Patient reported outcomes with completed SF-36 questionnaires were available in 28 patients (14 females). Over 24 months, significant improvement of pain and life role limitations due to physical activity was reported (Pain: change from baseline: 8.57 points, 95%-CI: 1.32-15.82, p = 0.022; role limitations physical: change from baseline: 13.39 points, 95%-CI: 0.61-23.2, p = 0.048).

CONCLUSION

Migalastat therapy adherence in FD-patients was high and remained high over a follow-up period of 2 years. Patient reported quality of life remained mostly stable, while pain and physical limitations improved over time.

Для цитирования: Müntze Jonas, Lau Kolja, Cybulla Markus, Brand Eva, Cairns Tereza, Lorenz Lora, Üçeyler Nurcan, Sommer Claudia, Wanner Christoph, Nordbeck Peter. Patient reported quality of life and medication adherence in Fabry disease patients treated with migalastat: A prospective, multicenter study.. Molecular genetics and metabolism. 2022. DOI: 10.1016/j.ymgme.2022.106981.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.